Poxel SAS

188 articles about Poxel SAS

• Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

  3/15/2023

  POXEL SA announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023.

• Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

  3/7/2023

  POXEL SA, clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced publication in Journal of Hepatology of positive results for DESTINY-1, a 36-week dose-ranging Phase 2 trial.

• Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  3/1/2023

  POXEL SA announced the publication of preclinical results in autosomal dominant polycystic kidney disease for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase activator.

• Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update

  2/15/2023

  POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL) today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2022.

• Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy

  1/25/2023

  POXEL SA announced that European Commission has granted orphan drug designation for PXL770 and PXL065 for the treatment of adrenoleukodystrophy.

• Poxel Announces Upcoming Participation at Investor Conferences - Jan 04, 2023

  1/4/2023

  POXEL SA announced its upcoming participation at conferences organized by Oddo BHF and Degroof Petercam to be held in January 2023.

• Poxel Announces its Financial Calendar for 2023

  1/3/2023

  POXEL SA today announced its calendar for the publication of financial information for 2023.

• Poxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update

  12/22/2022

  POXEL SA announced the drawdown of the remaining two tranches of the convertible bonds as part of the equity-linked financing facility with Iris Capital Investment representing a total of EUR 2 million.

• Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022

  11/8/2022

  POXEL SA provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2022.

• Poxel Announces Upcoming Participation at the Jefferies 2022 London Healthcare Conference

  11/7/2022

  POXEL SA announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.

• Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

  11/7/2022

  POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) were presented during the late-breaking session at The Liver Meeting® 2022.

• Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference

  10/13/2022

  Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference.

• Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

  10/12/2022

  POXEL SA announced that its late-breaking abstract describing the results from its Phase 2 study of PXL065 in NASH has been selected for an oral presentation at The Liver Meeting® 2022, hosted by the American Association for the Study of Liver Diseases, being held on November 4-8, 2022 in Washington, D.C.

• 

  FDA Review: Alnylam, Cytokinetics, Eli Lilly and More

  10/7/2022

  The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.

• Availability of Poxel's 2022 Half-Year Financial Report

  10/4/2022

  POXEL SA, a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic diseases, announces the publication of its half-year financial report as of June 30, 2022.

• Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

  10/3/2022

  POXEL SA announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease.

• Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update

  9/21/2022

  POXEL SA announced its financial results for the period ended June 30, 2022 and provided a corporate update.

• Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone

  9/21/2022

  POXEL SA announced positive histology results for DESTINY-1, the dose-ranging Phase 2 trial of PXL065 for the treatment of NASH.

• 

  Poxel's Positive Phase II Data Sparks More Momentum in NASH Space

  9/21/2022

  Poxel presented positive histology data from its Phase II DESTINY-1 trial in non-alcoholic steatohepatitis (NASH), with its primary efficacy endpoint of liver fat decrease at 36 weeks.

• Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022

  8/8/2022

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2022.